Inventor
Wei He
Inventor
Audubon, PA, US
Overview
Patents· 89 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
A61Pprimary
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations25%
A61KPreparations for medical, dental or toiletry purposes23%
C07DHeterocyclic compounds19%
C12NMicroorganisms or enzymes11%
C07KPeptides7%
C07CAcyclic or carbocyclic compounds6%
Y10STechnical subjects covered by former uspc cross-reference art collections [xracs] and digests3%
G01NInvestigating or analysing materials by determining their chemical or physical properties2%
A61NElectrotherapy1%
C07FAcyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium1%
PatentTitleYear
10,836,749Substituted quinoline-8-carbonitrile derivatives having androgen receptor degradation activity and uses thereof202010,800,770Chroman derivatives having estrogen receptor degradation activity and uses thereof202010,696,659Compounds having estrogen receptor alpha degradation activity and uses thereof202010,596,183Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases202010,537,587Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases202010,463,721Engineered chimeric pegylated ADI and methods of use201910,300,066Polyfluorinated compounds acting as bruton tyrosine kinase inhibitors201910,213,415Compounds as opioid receptor modulators201910,098,900Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases201810,081,629Amide derivatives and pharmaceutically acceptable salts thereof, preparation method thereof and medicinal application thereof20189,938,355Antibodies to argininosuccinate synthase and related methods20189,861,636'Polyfluorinated compounds acting as bruton tyrosine kinase inhibitors'20189,717,745'Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases'20179,700,542'Compounds as opioid receptor modulators'20179,644,038'Apolipoprotein nanodiscs with telodendrimer'20179,532,990'Polyfluorinated compounds acting as bruton tyrosine kinase inhibitors'20179,359,370'Icotinib hydrochloride, synthesis, crystalline forms, pharmaceutical compositions, and uses thereof'20169,205,076'Compounds as opioid receptor modulators'20159,079,861'Cyclic urea inhibitors of 11β-hydroxysteroid dehydrogenase 1'20158,927,715'Inhibitors of 11β-hydroxysteroid dehydrogenase type 1'20158,895,573'Phenoxy-substituted pyrimidines as opioid receptor modulators'20148,846,655'4-substituted-2-phenoxy-phenylamine delta opioid receptor modulators'20148,822,482'Icotinib hydrochloride, synthesis, crystalline forms, pharmaceutical compositions, and uses thereof'20148,772,325'Compounds as opioid receptor modulators'20148,748,444'Cyclic urea inhibitors of 11β-hydroxysteroid dehydrogenase 1'20148,685,990'Pyrimidine compounds as delta opioid receptor modulators'20148,609,709'Compounds as opioid receptor modulators'20138,575,156'Cyclic inhibitors of 11β-hydroxysteroid dehydrogenase 1'20138,513,271'Pyrimidine compounds as delta opioid receptor modulators'20138,440,652'MST1 kinase inhibitors and methods of their use'20138,440,658'Cyclic urea inhibitors of 11β-hydroxysteroid dehydrogenase 1'20138,394,809'Phenoxy-substituted pyrimidines as opioid receptor modulators'20138,383,629'Inhibitors of 11β-hydroxysteroid dehydrogenase type 1'20138,372,973'Prokineticin 1 receptor antagonists'20138,362,247'Prokineticin 1 receptor antagonists'20138,344,011'Compounds as opioid receptor modulators'20138,324,380'Amino-heteroaryl-containing prokineticin 1 receptor antagonists'20128,309,299'Combination therapy and method for assessing resistance to treatment'20127,968,710'Prokineticin 1 receptor antagonists'20117,902,358'Prokineticin 1 receptor antagonists'20117,892,773'Antibodies to human NK3-related prostate specific gene 1 proteins'20117,786,158'Compounds as opioid receptor modulators'20107,741,356'Compounds as opioid receptor modulators'20107,741,055'Prostatic growth factor'20107,659,402'Piperidines as opioid receptor modulators'20107,629,488'Process for the preparation of opioid modulators'20097,612,075'Substituted oxoazaheterocyclyl compounds'20097,416,855'Immunoassay methods for detecting interleukin-1 β converting enzyme like apoptosis protease-3'20087,351,694'Human NK-3 related prostate specific gene-1'20087,282,351'Prostatic growth factor'20077,202,381'Compounds as opioid receptor modulators'20077,132,282'Genetic modification of C57 mice'20067,115,260'Interleukin-1β converting enzyme like apoptotic protease-6'20067,083,930'Human choline acetyltransferase'20067,041,681'Compounds as opioid receptor modulators'20067,026,140'Serum paraoxonase'20066,960,597'Aza-bridged-bicyclic amino acid derivatives as α4 integrin antagonists'20056,890,721'Interleukin-1β converting enzyme like apoptotic protease-6'20056,852,712'Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases'20056,835,555'Interleukin-1 converting enzyme like apoptosis protease-3 and 4'20046,821,962'Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and /or p56lck tyrosine kinases'20046,733,981'Antibodies to interleukin-1 converting enzyme like apoptosis protease-3 and 4'20046,696,434'Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases'20046,656,743'Human choline acetyltransferase'20036,617,129'Human NK-3 related prostate specific gene-1'20036,538,121'Interleukin-1 converting enzyme like apoptosis protease-3 and 4'20036,528,526'Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases'20036,521,227'Polynucleotides encoding prostatic growth factor and process for producing prostatic growth factor polypeptides'20036,500,638'Prostatic growth factor'20026,495,519'Interleukin-1 converting enzyme like apoptosis protease-3 and 4'20026,482,834'Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases'20026,432,708'Human choline acetyltransferase'20026,344,198'Human prostatic specific reductase'20026,319,700'Human choline acetyltransferase'20016,316,193'Rapid-screen cDNA library panels'20016,294,169'Interleukin-1 beta converting enzyme like apoptotic protease-6'20016,245,540'Human choline acetyltransferase'20016,245,760'Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases'20016,180,632'Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases'20016,140,093'Polynucleotides encoding paraoxonase'20006,106,829'Human prostatic specific reductase'20006,087,150'Interleukin-1 .beta. converting enzyme like apoptosis protease-3 and 4'20006,010,878'Interleukin-1 .beta. converting enzyme like apoptotic protease-6'20005,994,102'Polynucleotides encoding prostatic growth factor and process for producing prostatic growth factor polypeptides'19995,792,639'Paraoxonase polypeptides and use therefor'19985,786,204'Human prostatic specific reductase'19985,629,193'Paraoxonase'19975,547,854'DNA encoding a receptor for Mullerian inhibitory substance, misr1, and corresponding vectors, cells, probes, and recombinant methods'19965,538,892'Nucleic acids encoding a TGF-.beta. type 1 receptor'1996Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
1996–2011Based in Columbia, MD, US· patent location history
1997–2011Patents assigned to HUMAN GENOME SCIENCES INC (27)· patent assignee history
2001–2005Based in Collegeville, PA, US· patent location history
2002–2009Patents assigned to AVENTIS PHARMA INC (6)· patent assignee history
2006–2019Patents assigned to JANSSEN PHARMACEUTICA NV (22)· patent assignee history
2006–2020Based in Audubon, PA, US· patent location history
2012–2018Patents assigned to HE WEI (18)· patent assignee history
2017–2020Patents assigned to ZHEJIANG DTRM BIOPHARMA CO LTD (7)· patent assignee history
2018–2019Based in San Diego, CA, US· patent location history
2020Based in Zionsville, IN, US· patent location history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| HUMAN GENOME SCIENCES INC | 27 | 1997–2011 |
| JANSSEN PHARMACEUTICA NV | 22 | 2006–2019 |
| HE WEIself | 18 | 2012–2018 |
| ZHEJIANG DTRM BIOPHARMA CO LTD | 7 | 2017–2020 |
| AVENTIS PHARMA INC | 6 | 2002–2009 |
Locations
| Location | Patents | Span |
|---|---|---|
| Audubon, Pennsylvania, US | 34 | 2006–2020 |
| Columbia, Maryland, US | 31 | 1996–2011 |
| Collegeville, Pennsylvania, US | 7 | 2001–2005 |
| Zionsville, IN, US | 3 | 2020 |
| San Diego, California, US | 2 | 2018–2019 |